Updated

Analysts examined how concerned income-focused investors should be about the sustainability of Pfizer's dividend, amid ongoing pressures facing the pharmaceutical giant's earnings and cash flow. The scrutiny reflects broader investor concern over payout ratios among large pharmaceutical companies facing patent cliffs and shifting revenue mixes.